Hard to say whether this will have a material change to...

  1. 676 Posts.
    lightbulb Created with Sketch. 133
    Hard to say whether this will have a material change to revenues. Per the 2022 annual report, Hizentra sales were up 20% during 2022 and is the market leading product for subcutaneous immunoglobulin products.

    Page 15 of the annual report shows that patients have a preference for Hizentra for at home dosing, so the pre-filled syringe is an obvious move to make.

    Appears to not be all upside as this has lead to a decline in Privigen sales.

    DYOR, IMO, blah blah
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$267.92
Change
-1.640(0.61%)
Mkt cap ! $129.7B
Open High Low Value Volume
$269.56 $270.42 $267.15 $252.9M 957.6K

Buyers (Bids)

No. Vol. Price($)
1 879 $267.91
 

Sellers (Offers)

Price($) Vol. No.
$268.98 120 1
View Market Depth
Last trade - 16.10pm 25/07/2025 (20 minute delay) ?
CSL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.